User login
Key clinical point: Enasidenib was associated with superior overall survival (OS) compared to standard of care (SoC) therapies in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation who were ineligible for hematopoietic stem cell transplantation (HSCT).
Major finding: Enasidenib vs. SoC was associated with a significantly longer OS (hazard ratio 0.67; 95% CI 0.47-0.97).
Study details: Findings are from a propensity score-matching analysis including adult patients with R/R AML with an IDH2 mutation ineligible for HSCT treated with enasidenib (n=195) from the AG221 C-001 trial or SoC therapies (n=78) from the French Chart Review study.
Disclosures: This study was sponsored and funded by Bristol Myers Squibb Some investigators, including the lead author, reported ties with various pharmaceutical companies, including Bristol Myers Squibb.
Source: de Botton S et al. Cancer Med. 2021 Aug 24. doi: 10.1002/cam4.4182.
Key clinical point: Enasidenib was associated with superior overall survival (OS) compared to standard of care (SoC) therapies in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation who were ineligible for hematopoietic stem cell transplantation (HSCT).
Major finding: Enasidenib vs. SoC was associated with a significantly longer OS (hazard ratio 0.67; 95% CI 0.47-0.97).
Study details: Findings are from a propensity score-matching analysis including adult patients with R/R AML with an IDH2 mutation ineligible for HSCT treated with enasidenib (n=195) from the AG221 C-001 trial or SoC therapies (n=78) from the French Chart Review study.
Disclosures: This study was sponsored and funded by Bristol Myers Squibb Some investigators, including the lead author, reported ties with various pharmaceutical companies, including Bristol Myers Squibb.
Source: de Botton S et al. Cancer Med. 2021 Aug 24. doi: 10.1002/cam4.4182.
Key clinical point: Enasidenib was associated with superior overall survival (OS) compared to standard of care (SoC) therapies in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation who were ineligible for hematopoietic stem cell transplantation (HSCT).
Major finding: Enasidenib vs. SoC was associated with a significantly longer OS (hazard ratio 0.67; 95% CI 0.47-0.97).
Study details: Findings are from a propensity score-matching analysis including adult patients with R/R AML with an IDH2 mutation ineligible for HSCT treated with enasidenib (n=195) from the AG221 C-001 trial or SoC therapies (n=78) from the French Chart Review study.
Disclosures: This study was sponsored and funded by Bristol Myers Squibb Some investigators, including the lead author, reported ties with various pharmaceutical companies, including Bristol Myers Squibb.
Source: de Botton S et al. Cancer Med. 2021 Aug 24. doi: 10.1002/cam4.4182.